The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers

References

• Dardenne E, Pierredon S, Driouch K, Gratadou L, Lacroix-Triki M, Espinoza MP, Zonta E, Germann S, Mortada H, Villemin JP, et al. Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol 2012; 19:1139 - 46; http://dx.doi.org/10.1038/nsmb.2390; PMID: 23022728
   PubMed Web of Science ®Google Scholar
• Guil S, Gattoni R, Carrascal M, Abián J, Stévenin J, Bach-Elias M. Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation. Mol Cell Biol 2003; 23:2927 - 41; http://dx.doi.org/10.1128/MCB.23.8.2927-2941.2003; PMID: 12665590
   PubMed Web of Science ®Google Scholar
• Liu ZR. p68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5′ splice site duplex. Mol Cell Biol 2002; 22:5443 - 50; http://dx.doi.org/10.1128/MCB.22.15.5443-5450.2002; PMID: 12101238
   PubMed Web of Science ®Google Scholar
• Fukuda T, Yamagata K, Fujiyama S, Matsumoto T, Koshida I, Yoshimura K, Mihara M, Naitou M, Endoh H, Nakamura T, et al. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol 2007; 9:604 - 11; http://dx.doi.org/10.1038/ncb1577; PMID: 17435748
   PubMed Web of Science ®Google Scholar
• Jalal C, Uhlmann-Schiffler H, Stahl H. Redundant role of DEAD box proteins p68 (Ddx5) and p72/p82 (Ddx17) in ribosome biogenesis and cell proliferation. Nucleic Acids Res 2007; 35:3590 - 601; http://dx.doi.org/10.1093/nar/gkm058; PMID: 17485482
   PubMed Web of Science ®Google Scholar
• Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, et al. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 2008; 68:7938 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-08-0932; PMID: 18829551
   PubMed Web of Science ®Google Scholar
• Wortham NC, Ahamed E, Nicol SM, Thomas RS, Periyasamy M, Jiang J, Ochocka AM, Shousha S, Huson L, Bray SE, et al. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer. Oncogene 2009; 28:4053 - 64; http://dx.doi.org/10.1038/onc.2009.261; PMID: 19718048
   PubMed Web of Science ®Google Scholar
• Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, Wardrop J, Gregory DJ, Lane DP, Perkins ND, Fuller-Pace FV. The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J 2005; 24:543 - 53; http://dx.doi.org/10.1038/sj.emboj.7600550; PMID: 15660129
   PubMed Web of Science ®Google Scholar
• Métivier R, Penot G, Hübner MR, Reid G, Brand H, Kos M, Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003; 115:751 - 63; http://dx.doi.org/10.1016/S0092-8674(03)00934-6; PMID: 14675539
   PubMed Web of Science ®Google Scholar
• Yang L, Lin C, Zhao S, Wang H, Liu ZR. Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J Biol Chem 2007; 282:16811 - 9; http://dx.doi.org/10.1074/jbc.M610488200; PMID: 17412694
   PubMed Web of Science ®Google Scholar
• Causevic M, Hislop RG, Kernohan NM, Carey FA, Kay RA, Steele RJ, Fuller-Pace FV. Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. Oncogene 2001; 20:7734 - 43; http://dx.doi.org/10.1038/sj.onc.1204976; PMID: 11753651
   PubMed Web of Science ®Google Scholar
• Shin S, Rossow KL, Grande JP, Janknecht R. Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res 2007; 67:7572 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-4652; PMID: 17699760
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402 - 12; http://dx.doi.org/10.1038/nrm2395; PMID: 18431400
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275 - 83; http://dx.doi.org/10.1038/nrm2147; PMID: 17380161
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413 - 31; http://dx.doi.org/10.1016/j.cell.2009.04.037; PMID: 19410540
   PubMed Web of Science ®Google Scholar
• Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223:116 - 26; http://dx.doi.org/10.1002/path.2784; PMID: 21125670
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15:2 - 8; http://dx.doi.org/10.1038/ncb2641; PMID: 23263379
   PubMed Web of Science ®Google Scholar
• Nicol SM, Bray SE, Black HD, Lorimore SA, Wright EG, Lane DP, Meek DW, Coates PJ, Fuller-Pace FV. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage. Oncogene 2013; 32:3461 - 9; http://dx.doi.org/10.1038/onc.2012.426; PMID: 22986526
   PubMed Web of Science ®Google Scholar
• Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10:265 - 75; http://dx.doi.org/10.1038/nrm2653; PMID: 19305416
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643 - 60; http://dx.doi.org/10.1038/nrd3184; PMID: 20671765
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321 - 30; http://dx.doi.org/10.1038/nrc1841; PMID: 16557283
   PubMed Web of Science ®Google Scholar
• Dietzmann K, Kirches E, von Bossanyi, Jachau K, Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001; 53:1 - 11; http://dx.doi.org/10.1023/A:1011808200978; PMID: 11678424
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyoshi E, Sasaki N, Kakudo K, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004; 90:414 - 8; http://dx.doi.org/10.1038/sj.bjc.6601540; PMID: 14735186
   PubMed Web of Science ®Google Scholar
• Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:2794 - 7; PMID: 10383133
   PubMed Web of Science ®Google Scholar
• Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29:354 - 8; http://dx.doi.org/10.1034/j.1600-0560.2002.290605.x; PMID: 12135466
   PubMed Web of Science ®Google Scholar
• Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94:148 - 52; http://dx.doi.org/10.1111/j.1349-7006.2003.tb01411.x; PMID: 12708489
   PubMed Web of Science ®Google Scholar
• Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999; 15:687 - 92; PMID: 10493949
   PubMed Web of Science ®Google Scholar
• Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M, Dietel M, Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90:815 - 21; http://dx.doi.org/10.1038/sj.bjc.6601610; PMID: 14970859
   PubMed Web of Science ®Google Scholar
• Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M, Denkert C. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005; 446:442 - 50; http://dx.doi.org/10.1007/s00428-005-1212-8; PMID: 15785925
   PubMed Web of Science ®Google Scholar
• Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60:240 - 5; http://dx.doi.org/10.1002/pros.20050; PMID: 15176053
   PubMed Web of Science ®Google Scholar
• Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14:543 - 9; http://dx.doi.org/10.1038/sj.onc.1200862; PMID: 9053852
   PubMed Web of Science ®Google Scholar
• Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23:5901 - 11; http://dx.doi.org/10.1038/sj.onc.1207782; PMID: 15221005
   PubMed Web of Science ®Google Scholar
• Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, Bleyl U. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000; 196:753 - 9; PMID: 11186170
   PubMed Web of Science ®Google Scholar
• Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279:25549 - 61; http://dx.doi.org/10.1074/jbc.M314182200; PMID: 15024021
   PubMed Web of Science ®Google Scholar
• Incassati A, Patel D, McCance DJ. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene 2006; 25:2444 - 51; http://dx.doi.org/10.1038/sj.onc.1209276; PMID: 16369493
   PubMed Web of Science ®Google Scholar
• Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 2004; 279:21183 - 92; http://dx.doi.org/10.1074/jbc.M311912200; PMID: 15016801
   PubMed Web of Science ®Google Scholar
• Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000; 2:672 - 6; http://dx.doi.org/10.1038/35023629; PMID: 10980711
   PubMed Web of Science ®Google Scholar
• Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr., Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009; 106:3964 - 9; http://dx.doi.org/10.1073/pnas.0813333106; PMID: 19225112
   PubMed Web of Science ®Google Scholar
• van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005; 24:2844 - 59; http://dx.doi.org/10.1038/sj.onc.1208617; PMID: 15838519
   PubMed Web of Science ®Google Scholar
• van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. J Biol Chem 2001; 276:41656 - 60; http://dx.doi.org/10.1074/jbc.M101831200; PMID: 11514540
   PubMed Web of Science ®Google Scholar
• Zhu H, Chang BD, Uchiumi T, Roninson IB. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1). Cell Cycle 2002; 1:59 - 66; http://dx.doi.org/10.4161/cc.1.1.101; PMID: 12429910
   PubMed Web of Science ®Google Scholar
• McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010; 9:4200 - 12; http://dx.doi.org/10.4161/cc.9.20.13532; PMID: 20962589
   PubMed Web of Science ®Google Scholar
• King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Meek DW. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. Breast Cancer Res 2012; 14:R40; http://dx.doi.org/10.1186/bcr3136; PMID: 22405092
   PubMedGoogle Scholar
• Hirling H, Scheffner M, Restle T, Stahl H. RNA helicase activity associated with the human p68 protein. Nature 1989; 339:562 - 4; http://dx.doi.org/10.1038/339562a0; PMID: 2471939
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497 - 501; http://dx.doi.org/10.1126/science.282.5393.1497; PMID: 9822382
   PubMed Web of Science ®Google Scholar
• Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, et al. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 2009; 9:307; http://dx.doi.org/10.1186/1471-2407-9-307; PMID: 19723334
   PubMed Web of Science ®Google Scholar
• Caretti G, Schiltz RL, Dilworth FJ, Di Padova M, Zhao P, Ogryzko V, Fuller-Pace FV, Hoffman EP, Tapscott SJ, Sartorelli V. The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell 2006; 11:547 - 60; http://dx.doi.org/10.1016/j.devcel.2006.08.003; PMID: 17011493
   PubMed Web of Science ®Google Scholar
• Mazurek A, Luo W, Krasnitz A, Hicks J, Powers RS, Stillman B. DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. Cancer Discov 2012; 2:812 - 25; http://dx.doi.org/10.1158/2159-8290.CD-12-0116; PMID: 22750847
   PubMed Web of Science ®Google Scholar
• Rossow KL, Janknecht R. Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300. Oncogene 2003; 22:151 - 6; http://dx.doi.org/10.1038/sj.onc.1206067; PMID: 12527917
   PubMed Web of Science ®Google Scholar
• Buszczak M, Spradling AC. The Drosophila P68 RNA helicase regulates transcriptional deactivation by promoting RNA release from chromatin. Genes Dev 2006; 20:977 - 89; http://dx.doi.org/10.1101/gad.1396306; PMID: 16598038
   PubMed Web of Science ®Google Scholar
• Lin C, Yang L, Yang JJ, Huang Y, Liu ZR. ATPase/helicase activities of p68 RNA helicase are required for pre-mRNA splicing but not for assembly of the spliceosome. Mol Cell Biol 2005; 25:7484 - 93; http://dx.doi.org/10.1128/MCB.25.17.7484-7493.2005; PMID: 16107697
   PubMed Web of Science ®Google Scholar
• Guo J, Hong F, Loke J, Yea S, Lim CL, Lee U, Mann DA, Walsh MJ, Sninsky JJ, Friedman SLA. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem 2010; 285:5428 - 37; http://dx.doi.org/10.1074/jbc.M109.035295; PMID: 20022962
   PubMed Web of Science ®Google Scholar
• Moore HC, Jordan LB, Bray SE, Baker L, Quinlan PR, Purdie CA, Thompson AM, Bourdon JC, Fuller-Pace FV. The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer. Oncogene 2010; 29:6475 - 84; http://dx.doi.org/10.1038/onc.2010.381; PMID: 20818423
   PubMed Web of Science ®Google Scholar
• Baker L, Quinlan PR, Patten N, Ashfield A, Birse-Stewart-Bell LJ, McCowan C, Bourdon JC, Purdie CA, Jordan LB, Dewar JA, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer 2010; 102:719 - 26; http://dx.doi.org/10.1038/sj.bjc.6605540; PMID: 20104224
   PubMed Web of Science ®Google Scholar
• Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48:876 - 8; http://dx.doi.org/10.1136/jcp.48.9.876; PMID: 7490328
   PubMed Web of Science ®Google Scholar
• Quinlan PR, Reed C, Thompson A. INSPIRE: an integrated agent based system for hypothesis generation within cancer datasets. WI-IAT 2008; 3:587-90, 2008 IEEE/WIC/ACM International Conference on Web Intellegence and Intellegent Agent Technology.
   Google Scholar